Filing Details

Accession Number:
0001104659-16-159835
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-11-30 19:56:49
Reporting Period:
2016-11-28
Filing Date:
2016-11-30
Accepted Time:
2016-11-30 19:56:49
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1660719 Aralez Pharmaceuticals Inc. ARLZ () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1537250 Paul Robert Harris C/O Aralez Pharmaceuticals Inc.,
7100 West Credit Avenue, Suite 101
Mississauga A6 L5N 0E4
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares, Without Par Value Acquisiton 2016-11-28 20,000 $3.92 614,094 No 4 M Direct
Common Shares, Without Par Value Disposition 2016-11-28 20,000 $4.65 594,094 No 4 S Direct
Common Shares, Without Par Value Acquisiton 2016-11-29 104,778 $3.92 698,872 No 4 M Direct
Common Shares, Without Par Value Disposition 2016-11-29 104,778 $4.99 594,094 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Shares, Without Par Value Employee Stock Option (right to buy) Disposition 2016-11-28 20,000 $0.00 20,000 $3.92
Common Shares, Without Par Value Employee Stock Option (right to buy) Disposition 2016-11-29 104,778 $0.00 104,778 $3.92
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
104,778 2016-12-01 No 4 M Direct
0 2016-12-01 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Shares, Without Par Value 600,188 Indirect By spouse
Footnotes
  1. Price is presented in Canadian dollars.
  2. The exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2016, as amended.
  3. Price is presented in United States dollars.
  4. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2016, as amended.
  5. This transaction was executed in multiple trades at prices ranging from $4.76 to $5.10. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  6. The option was exercisable as of the Reporting Person's previous filing on Form 3, dated as of February 8, 2016.